南非HIV感染者2020-35年多替拉韦耐药预测:一项建模研究
该建模研究使用MARISA确定性房室模型,校准复现南非2005至2035年HIV-1疫情,预测多替拉韦耐药演变。
要点
- 接受多替拉韦方案且治疗失败者中,获得性耐药从2023年18.5%升至2035年41.7%。
- 传播性多替拉韦耐药从2023年0.1%升至2035年5.0%,快速换用蛋白酶抑制剂方案可减缓。
核心结论
- 多替拉韦方案虽维持较高病毒学抑制,但获得性和传播性多替拉韦耐药可能增加。
- 在HIV RNA监测、基因型耐药检测和换药选择稀缺的环境中,耐药增加可能更大。
研究设计与样本
- 建模研究,使用校准复现南非2005至2035年HIV-1疫情的MARISA确定性房室模型。
- 数据来自国际艾滋病流行病学数据库协作组织(IeDEA)和文献。
- 模型关键参数包括多替拉韦耐药突变的获得率、回复率、核苷类逆转录酶抑制剂耐药对多替拉韦耐药获得的影响、多替拉韦耐药对疗效的影响、传播多替拉韦耐药突变的概率与传播野生型HIV概率之比,以及多替拉韦方案病毒学失败者中可检测药物水平的比例。
- 模型结局为估计的传播性多替拉韦耐药和获得性多替拉韦耐药。
主要发现
- 2035年使用多替拉韦方案者中病毒抑制(病毒载量<1000拷贝/mL)比例估计为93%(不确定范围92.2-94.3)。
- 多替拉韦方案治疗失败者中获得性多替拉韦耐药从2023年18.5%(不确定范围12.5-25.4)升至2035年41.7%(29.0-54.0)。
- 传播性多替拉韦耐药从2023年0.1%(0.0-0.2)升至2035年5.0%(1.9-11.9)。
- 涉及快速换用蛋白酶抑制剂方案的耐药缓解策略可有效减少获得性多替拉韦耐药增加,并减缓传播性多替拉韦耐药增加。
关键数值与推荐
- 病毒抑制定义为病毒载量<1000拷贝/mL。
- 获得性多替拉韦耐药:2023年18.5%(12.5-25.4)升至2035年41.7%(29.0-54.0)。
- 传播性多替拉韦耐药:2023年0.1%(0.0-0.2)升至2035年5.0%(1.9-11.9)。
- 2035年多替拉韦方案病毒抑制比例93%(92.2-94.3)。
临床怎么用
- 原文未据此给出推荐。
- 原文结论指出多替拉韦方案维持较高病毒学抑制,但获得性和传播性耐药可能增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In response to increasing resistance to non-nucleoside reverse transcriptase inhibitors, millions of people living with HIV have switched to dolutegravir-based antiretroviral therapy, so understanding the possible emergence of dolutegravir resistance is essential. We aimed to predict how dolutegravir resistance in South Africa will change over time. METHODS: For this modelling study, we used the Modelling Antiretroviral Drug Resistance in South Africa (MARISA) model, a deterministic compartmental model calibrated to reproduce the HIV-1 epidemic in South Africa from 2005 to 2035 using data from the International Epidemiology Databases to Evaluate AIDS collaboration and the literature. Key parameters for modelling dolutegravir-resistance evolution were acquisition rates of dolutegravir-resistance mutations, reversion rates of dolutegravir-resistance mutations, the effect of resistance to nucleoside reverse transcriptase inhibitors on dolutegravir-resistance acquisition, the effect of dolutegravir resistance on dolutegravir-treatment efficacy, the probability of transmitting dolutegravir drug-resistance mutations compared with the probability of transmitting wild-type HIV, and the proportion of people with virologic failure on dolutegravir-based antiretroviral therapy with detectable drug levels. Model outcomes were estimated transmitted dolutegravir resistance and estimated acquired dolutegravir resistance. FINDINGS: We estimated a substantial increase in the number of individuals on dolutegravir-based antiretroviral therapy after its introduction in 2020, increasing from 0 to approximately 7 million people (7·08-7·15) living with HIV on dolutegravir in 2035. We estimated the proportion of people living with HIV with viral suppression (ie, viral load <1000 copies per mL) on dolutegravir-based antiretroviral therapy to be 93% (uncertainty range 92·2-94·3) in 2035. We estimated that acquired dolutegravir resistance in people living with HIV on failing dolutegravir-based antiretroviral therapy would increase rapidly, from 18·5% (uncertainty range 12·5-25·4) in 2023 to 41·7% (29·0-54·0) in 2035. For transmitted dolutegravir resistance, we estimated an increase from 0·1% (0·0-0·2) in 2023 to 5·0% (1·9-11·9) in 2035. We estimated that resistance-mitigation strategies involving rapid switching to protease-inhibitor-based antiretroviral therapy could effectively reduce the increase in acquired dolutegravir resistance and slow the increase in transmitted dolutegravir resistance. INTERPRETATION: Although dolutegravir-based antiretroviral therapy maintains high virological suppression, acquired and transmitted dolutegravir resistance are likely to increase. This increase will likely be greater in settings where HIV RNA monitoring, genotypic-resistance testing, and options to switch antiretroviral therapy regimens are scarce. FUNDING: US National Institutes of Health National Institute of Allergy and Infectious Diseases, Swiss National Science Foundation, and University of Zurich Research Priority Program Evolution in Action.
引用
- Loosli T, Han N, Hauser A, et al. Predicted dolutegravir resistance in people living with HIV in South Africa during 2020-35: a modelling study. Lancet Glob Health. 2025. PMID: 40155107. doi:10.1016/S2214-109X(24)00553-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。